IL5 and eosinophilic granulomatosis with polyangiitis: Mepolizumab (Nucala<sup>®</sup>) is a humanised monoclonal antibody that binds interleukin (IL)-5 and randomised controlled trials have shown that it effectively targets eosinophil-driven manifestations of EGPA.